Association of postoperative #influenza vaccine on overall mortality in patients undergoing curative surgery for solid #tumors

Recent findings have found that the influenza vaccine induces changes in the immune system in favor of anti‐tumor cytotoxicity. The aim in this study was to investigate if an influenza vaccine given in the postoperative period decreased overall and cancer‐specific mortality in patients undergoing curative surgery for solid cancers. We conducted a registry‐based national observational study in Denmark in the period January 1, 2010 to … Continue reading Association of postoperative #influenza vaccine on overall mortality in patients undergoing curative surgery for solid #tumors

Association of acute myocardial #infarction with #influenza: A nationwide observational study

Influenza may precipitate cardiovascular disease, but influenza typically peaks in winter, coinciding with other triggers of myocardial infarction (MI) such as low air temperature, high wind velocity, low atmospheric pressure, and short sunshine duration.. Weekly laboratory-confirmed influenza case reports were obtained from the Public Health Agency of Sweden from 2009 to 2016 and merged with the nationwide SWEDEHEART MI registry. Weekly incidence of MI was … Continue reading Association of acute myocardial #infarction with #influenza: A nationwide observational study

Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts

Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear.. ..A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza … Continue reading Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts

#Influenza #vaccine effectiveness 2019-2020 interim estimates

Annual vaccination against seasonal influenza is recommended for all U.S. persons aged ≥6 months. Effectiveness of seasonal influenza vaccine varies by season. What is added by this report? According to data from the U.S. Influenza Vaccine Effectiveness Network on 4,112 children and adults with acute respiratory illness during October 23, 2019–January 25, 2020, the overall estimated effectiveness of seasonal influenza vaccine for preventing medically attended, … Continue reading #Influenza #vaccine effectiveness 2019-2020 interim estimates

Predictors of #mortality of #influenza virus infections in a Swiss Hospital during four influenza seasons: Role of quick sequential organ failure assessment

..Thirty-day mortality was 6.0% (25 patients). Multivariate analysis revealed that infection due to A virus (P 0.035; OR 7.1; 95% CI 1.1–43.8), malnutrition (P < 0.001; OR 25.0; 95% CI 4.5–138.8), hospital-acquired infection (P 0.003; OR 12.2; 95% CI 2.3–65.1), respiratory insufficiency (PaO2/FiO2 < 300) (P < 0.001; OR 125.8; 95% CI 9.6–1648.7) and pulmonary infiltrate on X-ray (P 0.020; OR 6.0; 95% CI 1.3–27.0) … Continue reading Predictors of #mortality of #influenza virus infections in a Swiss Hospital during four influenza seasons: Role of quick sequential organ failure assessment

Oseltamivir plus usual care versus usual care for #influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial

Antivirals are infrequently prescribed in European primary care for influenza-like illness, mostly because of perceived ineffectiveness in real world primary care and because individuals who will especially benefit have not been identified in independent trials.. ..The estimated absolute mean benefit from oseltamivir was 1·02 days (95% [BCrI] 0·74–1·31) overall, and in the prespecified subgroups, ranged from 0·70 (95% BCrI 0·30–1·20) in patients younger than 12 … Continue reading Oseltamivir plus usual care versus usual care for #influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial